P136 COMPARATIVE EFFICIENCY OF METHOTREXATE AND AZATHIOPRINE IN ACTIVE ULCERATIVE COLITIS REFRACTORY TO STEROIDS
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Aims: To evaluate clinical efficiency of methotrexate and azathioprine in active ulcerative colitis (UC) refractory to steroids. Patients & Methods: 62 UC patients were included (30F;32M). Age was from 24 till 46 years, duration of UC 8.4± 4.1 years (with duration of relapse from above 6 month). 26 patients were at treatment with methotrexate (25mg/week), 36 -at treatment with azathioprine (2-2.5 mg/day). Results: Clinical and morphological remission at 16th week has been reached in 30.7% of cases in methotrexate group and 36.1% of cases in azathioprine group, significant decreasing of UC activity was in 40.1% and 38.9% accordingly. In 23.2% (methotrexate) and 22.2% (azathioprine) of cases it was not clinical and morphological improvement. During therapy it was possible to stop steroid therapy for 11 (42.3%) patients received methotrexate, and for 18 (50.0%) patients received azathioprine. It is important to note, that achievement of remissions was associated with the brief anamnesis (1-2 years), a male (r=0,628; p <0,001) and the beginning of disease in the age of more than 50 years (r=0,524; p <0,005) Aims: Adalimumab, a fully human monoclonal antibody targeting tumor necrosis factor, is approved for the treatment of adults with Crohn' s disease. The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool assessing the impact of disease on productivity. 1 We assessed the impact of adalimumab therapy in the CHOICE trial on WPAI scores in patients with Crohn' s disease who previously failed therapy with infliximab. Materials and Methods: CHOICE was a US-based, multicenter, open-label trial of 673 patients with moderately or severely active Crohn' s disease who failed infliximab therapy. Planned study duration was at least 8 weeks. After a minimum 8-week washout period since last infliximab dose, patients received adalimumab induction therapy of 160/80 mg at Weeks 0/2, followed by 40 mg every other week maintenance dosing. At/after 8 weeks, patients could be switched to adalimumab 40 mg weekly for failure/nonresponse. The WPAI tool, as adapted for Crohn' s disease, measures the percentage of overall impairment in work productivity (including absenteeism and presenteeism) and daily activity due to Crohn' s disease (0%=no impairment; 100%=total loss of work productivity or activity). A 7% change in WPAI score is considered the minimal clinically important change. 2 WPAI scores were recorded at baseline and at Weeks 4, 8, 12, and 24 of CHOICE. Paired t-tests assessed the changes from baseline in WPAI component scores. Results: The mean age was 40.8 years, 59% were female, and 91% Caucasian. The mean baseline daily activity impairment (57.9%, N=662) and total work productivity impairment (49.4% among 394 employed patients) scores indicated severe impairment. The table below displays the average changes in WPAI components from baseline. For all outcomes, a large improvement in productivity, as illustrated by negative mean changes in WPAI components, was observed at Week 4 and maintained throughout the study period. Sensitivity analysis using a subset of employed patients with complete WPAI data at all scheduled visits (n=122) was performed and yielded similar results. ) is a once-daily, highstrength (1.2g/tablet), prolonged-release formulation of 5-aminosalicylic acid (5-ASA). In this study, the safety and efficacy of MMX mesalazine when dosed once or twice daily, was evaluated in patients whose ulcerative colitis (UC) was in remission. Methods: Patients enrolled into this randomised, multicentre, open-label, long-term trial (SPD476-303) had previously had active mild-to-moderate UC and had achieved strictly-defined clinical and endoscopic remission (UC disease activity index ≤1 calculated as scores of 0 for rectal bleeding and stool frequency, a combined sigmoidoscopy and physcian' s global assessment score of ≤1, no mucosal friability, and at least a 1-point reduction in sigmoidoscopy score from baseline) in one of two phase III, MMX mesalazine studies. Additionally, patients not meeting the above criteria, but considered in remission by their physician, were enrolled into the study. Patients were randomised to receive MMX mesalazine 2.4g/d once daily (2 x 1.2g tablet) or twice daily (1 x 1.2g tablet twice daily) for 12 months. Results: A total of 459 patients were randomised, of whom 362 were in clinical and endoscopic remission at week 0, and 97 were deemed well enough to receive maintenance treatment. Of the 362 patients in strictly-defined remission at month 0, 68% in the once-daily and 72% in the twice-daily groups, remained in strictly-defined clinical and endoscopic remission (using the same criteria) at month 12 defined. The proportion of patients who had not clinically relapsed (defined as a need for alternative UC treatment), was 89 and 93%, in the once-and twice-daily groups respectively, at 12 months. MMX mesalazine was found to be well tolerated in both treatment arms. Conclusions: MMX mesalazine 2.4g/day (given once or twice daily), has been shown to be well tolerated and effective in maintaining clinical and endoscopic remission in UC, when administered as either a once-or twice-daily dose. As 2.4g/day therapy requires only two tablets, patient compliance may be improved by utilisation of a once-daily dosing regimen. In turn, this may lead to less frequent disease relapses. 
P139 INSIGHTS INTO PATIENT AND PHYSICIAN COMMUNICATION AND EXPECTATIONS: RESULTS OF A LARGE PAN-EUROPEAN SURVEY OF PHYSICIANS AND THEIR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Aim:
Clear, open physician-patient communication is critical for optimising patient outcomes. Crohn' s disease (CD) and ulcerative colitis (UC) have significant impact on patient quality of life (QoL); therefore, it is important to discuss the possible impact of treatment options on QoL. Insight into current practice and patients' expectations for treatment and outcomes provides important perspective on the focus of physician-patient interactions. Materials and Methods: 2105 patients and 300 gastroenterologists in 5 countries (Belgium, France, Italy, Spain, UK) completed questionnaires in MayOctober 2007 and May 2007, respectively, to enable greater understanding of current attitudes and perceptions of CD/UC patients toward their disease and physician-patient communication. Results: Only 36% of patients felt their physicians were likely to initiate discussion regarding disease impact on work, personal relationships, school or social activities, while 92% of physicians reported they are likely to initiate such discussions. Patients had 6 long-term treatment goals: -Avoiding surgery -Avoiding hospitalisation -Improving QoL -Healing bowel lining -Reducing pain/discomfort -Rapid system relief Improving QoL in CD and UC was cited as highly important by 88% of patients and 86% of physicians. Reducing pain and discomfort (83%) and healing sores lining the bowel (82%) were also important to patients. Remission based on relieving signs and symptoms and mucosal healing was important to physicians (53% CD, 59% UC). Interestingly, only 28% of patients reported that mucosal healing was explained to them by their physician, whereas 46% of physicians report that they discuss mucosal healing as a desired treatment outcome with their patients. Mucosal healing benefits most discussed with patients were better chance for long-term remission and improved QoL (42% and 38%, respectively). Patients used biologics because their physician recommended them (82%) and explained that treatment could improve QoL (39%). The majority of physicians reported that avoiding surgery and preserving the bowel (64% CD, 59% UC) were important. 74% of patients would prefer to keep surgery as a last resort in their options. Conclusions: This survey clearly illustrates that CD and UC have a significant negative impact on patients' lives, and therapies improving QoL, reducing pain and discomfort and healing the mucosa are most important to them. Clear differences exist between physicians' and patients' opinions on how frequently discussions around treatment outcomes occur. With the availability of therapies that can impact QoL and heal the mucosa, improving communication between patients and physicians could lead to improved outcomes; physicians should initiate discussions on QoL and treatment outcomes with patients to ensure that their needs are addressed. Background: Serum Pepsinogen I (PG I) level reliably correlates with the number of chief cells in the gastric corpus mucosa. Gastric heterotopia of the small intestine in Crohn' s disease (CD) has been well described and PG I & II noted on immunohistochemisty in the metaplastic pyloric and oxyntic glands in the ileum. Adiponectin levels are known to be elevated in patients with CD with mesenteric adipose tissue hypertrophy and not in patients with UC. ASCA has been associated with more proximal involvement rather than colonic CD. Diagnosis of small intestinal involvement in patients with CD has major implications on patient management. Aim: The aim of this pilot study was to use serum PG I, serum adiponectin and IgA and IgG ASCA levels to develop an algorithm that distinguishes patients with colonic CD from those with CD involving the small intestine. Methods: Serum was prospectively collected and stored at -80°C from patients with histologically proven CD. PG I levels (Biohit plc, Finland) and Adiponectin levels (B-bridge International, USA), IgA and IgG ASCA (Aesku Lab, Germany) were determined in duplicate by ELISA. Patients were grouped into those with small intestinal involvement and those with colonic CD. Differences between groups were tested using Mann-Whitney U test of significance. Results: Mean PG I levels in the small bowel CD group (n=18) was 97.89 ± 33.07 µg/l. Mean PG I levels in the colonic CD group (n=14) was 83.25 ± 29.74 µg/l (p=0.08). Mean Adiponectin levels in the small bowel CD group was 3.89 ± 1.87 ng/ml and in the colonic CD group was 2.65 ± 1.50 ng/ml (p=0.02). Area under the Receiver operating curve for Adiponectin was 0.74 and for Serum PG I was 0.68. A cut off value of more than 1.58 ng/ml for serum Adiponectin and more than 78 µg/l for serum PG I with either a positive IGA or IgG ASCA had a sensitivity of 88.9 %, specificity of 85.7% and overall accuracy of 87.5% in detecting small bowel involvement in CD. Only 2 patients each with colonic and small intestinal CD were misclassified. Conclusion: Adiponectin levels are significantly higher in CD patients with small bowel disease. This could be because patients with colonic CD alone are less likely to have mesenteric fat hypertrophy. Serum PG1 levels showed a trend towards significance among patients with small intestinal CD. This could reflect both gastric heterotropia in the small intestine as well as inflammation due to CD in the stomach. Further studies are required to confirm these findings. A combination of Adiponectin, PG I levels and ASCA serology could help in non-invasive diagnosis of small bowel involvement in patients with CD. Introduction: Breastfeeding during immunosuppressive treatment in inflammatory bowel disease (IBD) patients is critically discussed. Women receiving AZA or 6-mercaptopurine (6-MP) are discouraged from breastfeeding because of the potential risks of bone marrow suppression and infections in the neonates. Two recent studies in patients taking thiopurines for systemic lupus erythematosus, prevention of renal transplant rejection, autoimmune hepatits or Crohn' s disease (3 patients) could not detect 6-thioguanine nucleotides levels in neonatal blood. Aim: This is the first prospective study which assessed a potential risk for infections in offspring breastfed by mothers receiving AZA for CD. Patients & Methods: After appropriate counselling 11 women taking AZA (median 150 mg/d, range:100-250 mg/d) during pregnancy decided to breastfeed their babies under therapy. The median time of breastfeeding was 6 months (range:1-18 months). Altogether 15 neonates (f/m:6/9) were prospectively followed for median 3.3 years (range:0.6-6.0 years). Women were periodically asked in form of a personal interview about their offspring concerning general development, infections, antibiotic treatments, hospitalisation and vaccinations.
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